Rezolute (RZLT) Liabilities and Shareholders Equity (2011 - 2026)
Rezolute (RZLT) posted Liabilities and Shareholders Equity of $125.5 million for Q1 2026, down 9.5% sequentially from $138.6 million in Q4 2025, and up 32.43% YoY from $94.7 million in Q1 2025.
Analysis
Rezolute (RZLT) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends
Rezolute has reported Liabilities and Shareholders Equity for 16 years, with the latest figure at $125.5 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 32.43% year-over-year to $125.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $598.2 million (up 29.24% YoY) and the FY2025 annual result came in at $175.5 million, up 32.21% from the prior year.
- Liabilities and Shareholders Equity eased to $125.5 million in Q1 2026 per RZLT's latest filing, from $138.6 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $175.5 million in Q2 2025 and troughed at $69.6 million in Q1 2022.
- A 5-year average of $126.5 million and a median of $125.5 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity soared 302.45% in 2022, then slumped 34.62% in 2024.
- Over 5 years, Liabilities and Shareholders Equity stood at $150.2 million in 2022, then plunged by 31.99% to $102.1 million in 2023, then climbed by 9.65% to $112.0 million in 2024, then gained by 23.77% to $138.6 million in 2025, then dropped by 9.5% to $125.5 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $125.5 million, $138.6 million, and $158.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Rezolute | 477.02 Mn | 477.02 Mn | - | 125.46 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 125.46 Mn |
| Dec 31, 2025 | 138.63 Mn |
| Sep 30, 2025 | 158.66 Mn |
| Jun 30, 2025 | 175.49 Mn |
| Mar 31, 2025 | 94.74 Mn |
| Dec 31, 2024 | 112.01 Mn |
| Sep 30, 2024 | 123.41 Mn |
| Jun 30, 2024 | 132.74 Mn |
| Mar 31, 2024 | 87.74 Mn |
| Dec 31, 2023 | 102.15 Mn |
| Sep 30, 2023 | 113.00 Mn |
| Jun 30, 2023 | 123.72 Mn |
| Mar 31, 2023 | 134.21 Mn |
| Dec 31, 2022 | 150.21 Mn |
| Sep 30, 2022 | 155.99 Mn |
| Jun 30, 2022 | 152.42 Mn |
| Mar 31, 2022 | 69.57 Mn |
| Dec 31, 2021 | 83.41 Mn |
| Sep 30, 2021 | 38.76 Mn |
| Jun 30, 2021 | 42.61 Mn |